ArticleFrontiers in immunology2017
Hsp65-Producing
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Amino acid metabolism by pig intestinal bacteria and consequences for intestinal health and environment: current knowledge and future directions.Journal of animal science and biotechnology · 2026Review
- Article
- Lactococcus lactis-HSP65 requires TLR2 to induce tolerogenic dendritic cells and confer protection against type 1 diabetes in a murine model.Cellular and molecular life sciences : CMLS · 2025Article
- Dysbiosis and Therapeutic Modulation of the Gut Microbiota in Multiple Sclerosis: A Narrative Review.Health science reports · 2025Article
- Recycling of Undigested Proteins Provided by the Host to the Large Intestine Microbiota: Implication for Intestinal Bacterial Anabolism, Growth, and Physiology.Microorganisms · 2025Review
- The Role of Gut Microbiota on Intestinal Fibrosis in Inflammatory Bowel Disease and Traditional Chinese Medicine Intervention.Journal of inflammation research · 2025Review
- Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.Theranostics · 2025Review
- Recombinant probioticFrontiers in microbiology · 2024Article
- Atheroprotective Aspects of Heat Shock Proteins.International journal of molecular sciences · 2023Review
- Growth differentiation factor 11 delivered by dairyFrontiers in microbiology · 2023Article
- Article
- Encouraging Tactics with Genetically Modified Probiotics to Improve Immunity for the Prevention of Immune-Related Diseases including Cardio-Metabolic Disorders.Biomolecules · 2022Article
- Paraprobiotics and Postbiotics ofMicroorganisms · 2022Article
- Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens byInternational journal of molecular sciences · 2021Review
- Intake ofMicroorganisms · 2021Article
- Oral tolerance as antigen-specific immunotherapy.Immunotherapy advances · 2021Review
- Oral Tolerance Induced by Heat Shock Protein 65-ProducingFrontiers in immunology · 2021Article
- SlpB Protein Enhances the Probiotic Potential ofFrontiers in pharmacology · 2021Article
- Mycobacterial Hsp65 antigen delivered by invasive Lactococcus lactis reduces intestinal inflammation and fibrosis in TNBS-induced chronic colitis model.Scientific reports · 2020Article
- The Microbiome as a Therapeutic Target for Multiple Sclerosis: Can Genetically Engineered Probiotics Treat the Disease?Diseases (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat shock proteins (Hsps) are highly expressed at all sites of inflammation. As they are ubiquitous and immunodominant antigens, these molecules represent good candidates for the therapeutic use of oral tolerance in autoimmune and chronic inflammatory diseases. Evidences from human and animal studies indicate that inflammatory bowel disease (IBD) results from uncontrolled inflammatory responses to intestinal microbiota. Hsps are immunodominant proteins expressed by several immune cells and by commensal bacteria. Using an IBD mouse model, we showed that oral pretreatment with genetically modified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.